Immune Profile Score Algorithmic Test Is Now Available to Help Inform Checkpoint Inhibitor Use in Cancer

The Immune Profile Score (IPS) algorithmic test, which is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic solid tumors who are already considered candidates for immune checkpoint inhibitor–based therapy, is now available for clinical use.

Findings from a validation study being presented at the 2024 SITC Annual Meeting showed that patients with IPS-high scores in the study experienced an overall survival benefit when treated with immune checkpoint inhibitor–based therapy compared with patients who had IPS-low scores (HR, 0.45).

"This is Tempus’ first time leveraging a multimodal algorithm in the immunotherapy space, and we look forward to providing clinicians the ability to use our IPS test to garner data-driven insights that can inform important treatment decisions," Ezra Cohen, MD, chief medical officer of Oncology at Tempus, stated in a news release. "We are excited to introduce this innovative test to clinicians, empowering them with the ability to make more informed choices for their patients while simultaneously moving the field forward in meaningful ways."

The retrospective study used to validate the test included 1600 adult patients with 19 different metastatic and/or stage IV solid tumor types from a real-world, de-identified database compiled by Tempus.

Additional findings showed that IPS had prognostic utility independent of tumor mutational burden, PD-L1 immunohistochemistry, and microsatellite instability status in the study cohort.

Reference

Tempus announces the clinical launch of its Immune Profile Score algorithmic test. News release. Tempus AI. November 7, 2024. Accessed November 7, 2024. https://www.tempus.com/news/pr/tempus-announces-the-clinical-launch-of-its-immune-profile-score-algorithmic-test/